These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28662227)

  • 41. Optimization strategies for colpotomizer technology during total laparoscopic hysterectomy.
    Jackson T; Advincula AP
    Surg Technol Int; 2012 Dec; 22():183-8. PubMed ID: 23292676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 43. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 44. A patient-initiated postmarketing surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Psychopharmacol Bull; 1987; 23(3):400-4. PubMed ID: 3432511
    [No Abstract]   [Full Text] [Related]  

  • 45. Medical device postapproval safety monitoring: where does the United States stand?
    Rajan PV; Kramer DB; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):124-31. PubMed ID: 25563662
    [No Abstract]   [Full Text] [Related]  

  • 46. CooperSurgical Colpotomizer Koh Cups are being left in patients after uterine surgery.
    Health Devices; 2010 Feb; 39(2):65-6. PubMed ID: 21305896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA proposes higher fees for drug approvals to cover postmarketing surveillance.
    Tanne JH
    BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596
    [No Abstract]   [Full Text] [Related]  

  • 48. FDA Oversight of Postmarketing Studies.
    Kashoki M; Lee C; Stein P
    N Engl J Med; 2017 Sep; 377(12):1201-1202. PubMed ID: 28930501
    [No Abstract]   [Full Text] [Related]  

  • 49. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 50. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 51. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 52. Randomized controlled study comparing the Gynecare Morcellex and Rotocut G1 tissue morcellators.
    Zullo F; Falbo A; Iuliano A; Oppedisano R; Sacchinelli A; Annunziata G; Venturella R; Materazzo C; Tolino A; Palomba S
    J Minim Invasive Gynecol; 2010; 17(2):192-9. PubMed ID: 20226407
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 54. FDA warns against procedure used in removing fibroids.
    Stephenson J
    JAMA; 2014 May; 311(19):1956. PubMed ID: 24846021
    [No Abstract]   [Full Text] [Related]  

  • 55. The FDA's poor oversight of postmarketing studies.
    Lancet; 2009 Nov; 374(9701):1568. PubMed ID: 19897111
    [No Abstract]   [Full Text] [Related]  

  • 56. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug approval system questioned in US and Canada.
    Eggertson L
    CMAJ; 2005 Feb; 172(3):317-8. PubMed ID: 15684107
    [No Abstract]   [Full Text] [Related]  

  • 58. Postmarketing surveillance--lack of vigilance, lack of trust.
    Fontanarosa PB; Rennie D; DeAngelis CD
    JAMA; 2004 Dec; 292(21):2647-50. PubMed ID: 15572723
    [No Abstract]   [Full Text] [Related]  

  • 59. FDA fails to monitor fast tracked drugs after approval, says US watchdog.
    Dyer O
    BMJ; 2016 Jan; 532():i371. PubMed ID: 26791241
    [No Abstract]   [Full Text] [Related]  

  • 60. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.